POLITICIANS BUYING THE DIP

@barebone.ai

7.4K followers · usually 286 views a post

Views

21.0K

Likes

776

Comments

SoundTikTok sound · original sound - barebone.ai

Promoted product

Barebone

An agentic AI investment research terminal that puts an entire Wall Street institution behind every decision. Real-time data, fundamental analysis, smart-money tracking, and 24/7 AI portfolio monitoring — built by ex-Goldman Sachs bankers.

6 videos

Why it worked

The video effectively combines a trending topic (congressional stock trading) with a specific, controversial case study (Zoetis and Librela). It uses clear visuals, a compelling narrative of potential impropriety, and a direct call to action, making complex financial information accessible and engaging.

Summary

This video investigates suspicious stock trading activity by four members of Congress related to Zoetis (ZTS), a major animal health company. The stock's decline is linked to issues with their product Librela, which faced scrutiny from the FDA due to adverse effects in dogs. Despite the stock's crash, these politicians, some with oversight over the FDA, purchased Zoetis stock within the same month, raising questions about potential insider knowledge.

Structure

1Introduction to politicians buying the dip in Zoetis stock.
2Explanation of Zoetis and its product Librela, and the issues it faced.
3

Original caption

Four members of Congress bought the same dip. All within one month. On a pet stock that keeps getting destroyed. And two of them sit on the committee that oversees the exact agency behind the crash. These are the kind of investing insights every trader and investor needs before trading blind. Congress trades are public if you know where to look. Here is what they might know that you do not. The stock is Zoetis ($ZTS), one of the biggest animal health companies in the world. One product dragged it down. Librela, a treatment for arthritis pain in dogs. It was supposed to be a major growth driver. Then dogs started dying and adverse symptoms got reported. The FDA warned vets. Earnings missed. The stock crashed. Here is the suspicious part. Barebone flagged that four members of Congress started buying after the crash, all within one month. Ro Khanna, Gilbert Cisneros, Byron Donalds, and Charles Fleischmann. Now it gets complicated. Khanna and Donalds both sit on the House Oversight Committee, which has direct investigative oversight of the FDA. The same agency that warned about Librela. The product whose failure dragged Zoetis down since 2024. To be fair, you could argue the stock is simply cheap. It trades well below Wall Street price targets. Goldman Sachs, Morgan Stanley, and JP Morgan all say buy. Even Zoetis directors, the people who know the company best, kept buying too. But four politicians, two with investigative power over the FDA, all buying the same stock in the same month is at least worth a raised eyebrow. There is no public proof anyone traded on private information, and a committee seat does not make a purchase illegal. Call it coincidence. Call it smart dip buying. Either way, the public never hears about these trades in time. Comment "CONGRESS" To access the Congress Trade Tracker: top stocks Congress is buying, their best-performing politicians, their complete trade history, and the industries they are rotating into This content is for educational and informational purposes only and does not constitute financial advice. Always do your own research before making any investment decisions.

More from @barebone.ai

On-screen text

POLITICIANS BUYING THE DIP This pet stock keeps getting destroyed But these four members of Congress keep buying the dip This rabbit hole goes way deeper than that So here's what they know that you don't BAREBONE INVESTING SCHOOL DAY 76/100 And welcome back to Day 76 of the 100-Day Barebone Investing School ZOETIS ZTS #1 ANIMAL HEALTH $32.5B MARKET CAP Zoetis ticker ZTS is one of the biggest animal health companies in the world ZTS SHARE PRICE $180 $140 $100 $60 2024 2025 2026 Daily close Source: Barebone -61% SINCE 2024 THE DECLINE but one product became central to the stock's decline Librela a treatment LIBRELA DOG ARTHRITIS INJECTION for arthritis pain for dogs Now pay attention because this product is ZOETIS precisely what makes these Congress trades SUSPICIOUS TRADES even more suspicious LIBRELA projected sales EXPECTED: MAJOR GROWTH Librela was supposed to become a major Librela HARM FDA ADVERSE EVENTS REPORTED growth product but dogs started dying and reported adverse symptoms FDA U.S. FOOD & DRUG ADMINISTRATION FDA WARNS VETS This drew scrutiny from the FDA who warned vets about the problem Q RESULTS EARNINGS MISS That resulted in terrible earnings results ZTS Zoetis - Aug 2025 - Aug 2026 $160 $140 $120 $100 $80 SEP DEC MAR JUN AUG Source: Barebone 12-MONTH DROP -50% So the stock started crashing But here's what's really suspicious CONGRESS UNUSUAL TRADING FLAGGED U.S. CAPITOL BAREBONE SCAN ACTIVE But here's what's really suspicious BAREBONE Zoetis Inc. ZTS At close 77.52 USD -51.58 (-39.95%) Since Feb 26, 2026 Pre-Market 77.00 USD -0.52 (-0.67%) Visualizing Congress Trades but four Congress politicians Ro Khanna Gilbert Cisneros Byron Donalds Charles Fleischmann Ro Khanna Gilbert Cisneros Byron Donalds Charles Fleischmann started buying after the crash all within one month But here's where the story gets more complicated Ro Khanna and Byron Donalds HOUSE OVERSIGHT COMMITTEE both serve on the House Oversight Committee FDA OVERSEES THE FDA investigative oversight on the FDA The exact federal body that warned HOUSE OVERSIGHT FDA WARNING LIBRELA ZTS - SINCE 2024 DECLINE -60.6% ZTS SINCE 2024 Librela the product whose failure dragged Zoetis down since 2024 THE BULL CASE? ZTS Zoetis - 3 Months - 1-Hour Bars $84 $81 $78 $75 $72 JUN JUL AUG Source: Barebone THE DIP $71.68 LOW OFF THE LOWS +7.8% Now of course you can definitely argue that after the crash the stock is cheap and politicians were simply buying the dip Analyst Price Target Current: 77.52 Low 80.00 Median: 85.00 High 95.00 View more > Analyst Ratings Sell Strong Sell Hold Buy Strong Buy Hold View more > Manufacturers - ...a global leader in on the research In fact ZTS is currently way below the price targets of Wall Street analysts ZTS PROFILE Strong Sell 0 Major Bank Ratings Goldman Sachs Buy Maintain May 6, 2024 Morgan Stanley Buy Maintain Jul 22, 2026 JP Morgan Buy Maintain Aug 7, 2026 Bank of America Buy + Hold Downgrade Jul 1, 2019 Barclays Hold Maintain Jul 1, 2026 Citigroup Buy Maintain Aug 11, 2026 HSBC Buy Maintain Jul 6, 2026 UBS Hold Maintain Aug 7, 2026 Goldman Sachs Morgan Stanley JP Morgan all say buy Insider Trades ZTS BUY Bisaro Paul Director $152K May 13, 2026 $75.88 ZTS BUY Damelio Frank A Director $501K May 13, 2026 $75.39 ZTS BUY Mccallister Michael B Director $233K May 11, 2026 $75.39 Even the directors inside ZTS the people who know Zoetis best kept buying CONGRESS DISCLOSED BUYS KHANNA CISNEROS DONALDS FLEISCHMANN FDA POWER FDA POWER But it just seems rather dubious that four politicians of which two have investigative powers over the FDA all ZTS 4 BUYS AFTER THE CRASH bought Zoetis within the same month COINCIDENCE? SMART DIP-BUY? Call it coincidence call it smart dip-buy Explore Congress Super-Investors Socials Insider What Is Congress Buying? Tickers with the most overlapping congressional buys, ranked by member count. 90d GOOGL Alphabet Inc. 6 members T AT&T Inc. 4 members ZTS Zoetis Inc. 4 members Top Congress Trading Sectors See all > Disclosed congressional money is flowing by estimated trade amounts. Financial Services $135K Healthcare $244K Real Estate $191K But when Congress suddenly buys the same stock Barebone will be the first to tell you Recent Suspicious Trades Trades by members with committee conflicts. They may know more from that work. Michael Rulli GOOGL Alphabet Inc. HOUSE COMMITTEE Energy & Commerce STOCK SINCE SOLD Aug 24, 2020 SELL -1.7% Disclosed Amount $50K - $100K Traded Aug 24, 2020 M. Rulli sits on House Committee on Energy & Commerce, and sold $50,001 - $100,000 of Alphabet Inc.. Who Beats The Market? Estimated performance of disclosed congressional trades compared with the S&P 500 over the last 12 months All members 12 months 65 members estimated returns Kevin Hern R-OK House 45 disclosed trades +42.28% +23.81% vs S&P Jared Moskowitz D-FL House 67 disclosed trades +34.64% +18.17% vs S&P Julie Johnson D-TX House 200 disclosed trades +28.39% +9.92% vs S&P Michael Guest R-MS House 7 disclosed trades +26.40% +7.93% vs S&P Scott Franklin R-FL House 6 disclosed trades +26.22% +7.75% vs S&P Josh Gottheimer D-NJ House 7 disclosed trades +24.07% +3.71% vs S&P And see all the trades politicians even Donald Trump are buying BAREBONE Day 1: Top 100 Apple App Store Day 60: Top 10 Google Play COMMENT CONGRESS for access! Comment Congress and I'll send you access Goldman Sachs Making investing easier is why I quit Goldman Sachs to build Barebone BAREBONE INVESTMENT AI ENGINE Ask Anything Follow for the next episode

Transcript

Four members of Congress bought the same dip. All within one month. On a pet stock that keeps getting destroyed. And two of them sit on the committee that oversees the exact agency behind the crash. These are the kind of investing insights every trader and investor needs before trading blind. Congress trades are public if you know where to look. Here is what they might know that you do not. The stock is Zoetis ($ZTS), one of the biggest animal health companies in the world. One product dragged it down. Librela, a treatment for arthritis pain for dogs. Now pay attention because this product is precisely what makes these Congress trades suspicious. Even more suspicious. Librela was supposed to become a major growth product but dogs started dying and reported adverse symptoms. This drew scrutiny from the FDA who warned vets about the problem. That resulted in terrible earnings results. So the stock started crashing. But here's what's really suspicious. Barebone flagged that not one, not two, but four Congress politicians. Ro Khanna, Gilbert Cisneros, Byron Donalds, Charles Fleischmann started buying after the crash, all within one month. But here's where the story gets more complicated. Ro Khanna and Byron Donalds both serve on the House Oversight Committee. The committee that has direct investigative oversight on the FDA. The exact federal body that warned about Librela, the product whose failure dragged Zoetis down since 2024. The bull case? Now of course you can definitely argue that after the crash the stock is cheap and politicians were simply buying the dip. In fact ZTS is currently way below the price targets of Wall Street analysts. Goldman Sachs, Morgan Stanley, JP Morgan all say buy. Even the directors inside ZTS, the people who know Zoetis best kept buying. But it just seems rather dubious that four politicians of which two have investigative powers over the FDA, all bought Zoetis within the same month. Call it coincidence, call it smart dip-buy. But when Congress suddenly buys the same stock, Barebone will be the first to tell you. If you want to catch these Congress trades before everyone finds out, and see all the trades politicians even Donald Trump are buying. Comment CONGRESS and I'll send you access. Making investing easier is why I quit Goldman Sachs to build Barebone. Follow for the next episode.